查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
單純皰疹病毒治療市場 - 全球市場規模、佔有率、趨勢分析、機會和預測報告，2019-2029
市場調查報告書
商品編碼
1319312

單純皰疹病毒治療市場 - 全球市場規模、佔有率、趨勢分析、機會和預測報告，2019-2029

Herpes Simplex Virus Treatment Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019-2029, Segmented By Type ; By Drug Type ; By Distribution Channel ; By Region
出版日期: | 出版商: Blueweave Consulting | 英文 400 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

到 2029 年，全球單純皰疹病毒 (HSV) 治療市場規模將達到 21.7 億美元

由於HSV檢測和治療方法市場的不斷發展以及HSV感染患病率的上升，全球單純皰疹病毒（HSV）治療市場正在蓬勃發展。

領先的戰略諮詢和市場研究公司 BlueWeave Consulting 最近估計，2022 年全球單純皰疹病毒 (HSV) 治療市場規模為 17.3 億美元。 BlueWeave 預測，在 2023-2029 年預測期內，全球單純皰疹病毒 (HSV) 治療市場規模將以 3.83% 的年複合成長率成長，到 2029 年達到 21.7 億美元。全球單純皰疹病毒（HSV）治療市場的主要成長促進因素包括皰疹感染患病率的增加、對可用治療方案的認知提高、對有效治療的需求增加等。抗病毒藥物的更多採用和新型治療方法的開發進一步促進了市場成長。單純皰疹是一種廣泛傳播的皰疹病毒株，罹患世界上很大一部分人口，估計罹患約 37 億人。這種高度傳染性的感染可以通過多種體液傳播，包括唾液、陰道分泌物和精液，並且通常在感染者不知情的情況下傳播。在預測期內，COVID-19 患者（包括接種疫苗的患者）中人類皰疹病毒的溶血性再激活也顯著增加。然而，最常用的皰疹藥物的常見副作用預計將抑制全球單純皰疹病毒（HSV）治療市場的成長。

該報告的詳細分析提供了有關全球單純皰疹病毒（HSV）治療市場的成長潛力、未來趨勢和統計數據的資訊。它還涵蓋了推動市場總規模預測的因素。該報告致力於提供全球單純皰疹病毒（HSV）治療市場的最新技術趨勢以及行業見解，幫助決策者做出明智的戰略決策。它還分析了市場的成長促進因素、挑戰和競爭力。

目錄

第1章 研究框架

第2章 執行摘要

第3章 全球單純皰疹病毒 (HSV) 治療市場洞察

  • 行業價值鏈分析
  • DROC分析
    • 成長促進因素
      • 單純皰疹病毒感染的傳播
      • HSV 檢測和藥物開發的增加
    • 抑制因素
      • 最常用的皰疹藥物的常見副作用
    • 機會
      • 增加研發活動
      • 新興經濟體的高成長潛力
    • 任務
      • 與單純皰疹病毒相關的恥辱
  • 技術進步/最新發展
  • 監管框架
  • 波特五力分析
  • 價格分析：2019-2022年全球汽車存儲器

第4章 全球單純皰疹病毒（HSV）治療市場概述

  • 2019-2029 年市場規模和價值預測
    • 按金額
  • 市場佔有率及預測
    • 按類型
      • 單純皰疹病毒1型感染
      • 單純皰疹病毒2型感染
    • 按藥物類型
      • 阿昔洛韋
      • 伐昔洛韋
      • 泛昔洛韋
    • 按配銷通路
      • 醫院藥房
      • 藥店和零售藥店
      • 線上提供商
    • 按地區
      • 北美
      • 歐洲
      • 亞太地區 (APAC)
      • 拉丁美洲 (LATAM)
      • 中東和非洲 (MEA)

第5章 北美單純皰疹病毒（HSV）治療市場

  • 2019-2029 年市場規模和價值預測
    • 按金額
  • 市場佔有率及預測
    • 按類型
    • 按藥物類型
    • 按配銷通路
    • 按國家/地區
      • 美國
      • 加拿大

第6章 歐洲單純皰疹病毒（HSV）治療市場

  • 2019-2029 年市場規模和價值預測
    • 按金額
  • 市場佔有率及預測
    • 按類型
    • 按藥物類型
    • 按配銷通路
    • 按國家/地區
      • 德國
      • 英國
      • 義大利
      • 法國
      • 西班牙
      • 荷蘭
      • 其他歐洲國家

第7章 亞太地區單純皰疹病毒（HSV）治療市場

  • 2019-2029 年市場規模和價值預測
    • 按金額
  • 市場佔有率及預測
    • 按類型
    • 按藥物類型
    • 按配銷通路
    • 按國家/地區
      • 中國
      • 印度
      • 日本
      • 韓國
      • 澳大利亞和紐西蘭
      • 印度尼西亞
      • 馬來西亞
      • 新加坡
      • 菲律賓
      • 越南
      • 亞太地區其他地區

第8章 拉丁美洲單純皰疹病毒（HSV）治療市場

  • 2019-2029 年市場規模和價值預測
    • 按金額
  • 市場佔有率及預測
    • 按類型
    • 按藥物類型
    • 按配銷通路
    • 按國家/地區
      • 巴西
      • 墨西哥
      • 阿根廷
      • 秘魯
      • 哥倫比亞
      • 拉丁美洲其他地區

第9章 中東和非洲單純皰疹病毒（HSV）治療市場

  • 2019-2029 年市場規模和價值預測
    • 按金額
  • 市場佔有率及預測
    • 按類型
    • 按藥物類型
    • 按配銷通路
    • 按國家/地區
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 科威特
      • 南非
      • 奈及利亞
      • 阿爾及利亞
      • MEA 的其餘部分

第10章 競爭格局

  • 主要公司及其產品列表
  • 2022年全球單純皰疹病毒（HSV）治療產品企業市場佔有率分析
  • 通過運行參數進行競爭基準測試
  • 主要戰略發展（合併、收購、合作夥伴關係等）

第11章新型冠狀病毒病（COVID-19）對全球單純皰疹病毒（HSV）治療市場的影響

第12章公司簡介（公司簡介、財務矩陣、競爭格局、關鍵人才、主要競爭、聯繫地址、戰略展望和SWOT分析）

  • Abbott Laboratories
  • Pfizer, Inc.
  • Amneal Pharmaceuticals, Inc.
  • GlaxoSmithKline PLC
  • Teva Pharmaceuticals Industries Ltd.
  • Glenmark Pharmaceuticals Limited
  • Fresenius SE & Co. KGaA
  • Novartis AG
  • Viatris, Inc.
  • Emcure Pharmaceuticals Limited
  • Other Prominent Players

第13章關鍵戰略建議

第14章調查方法

  • 定性研究
    • 初級和次級研究
  • 定量研究
  • 市場細分和數據三角測量
    • 二次調查
    • 初步調查
  • 主要調查受訪者的地區分佈
  • 假設和限制
簡介目錄
Product Code: BWC23615

Global Herpes Simplex Virus (HSV) Treatment Market Size Set to Touch USD 2.17 Billion by 2029.

Global herpes simplex virus (HSV) treatment market is flourishing because of an increasing development of HSV testing and medications and rising prevalence of HSV infections.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated global herpes simplex virus (HSV) treatment market size at USD 1.73 billion in 2022. During the forecast period between 2023 and 2029, BlueWeave expects global herpes simplex virus (HSV) treatment market size to grow at a CAGR of 3.83% reaching a value of USD 2.17 billion by 2029. Major growth drivers for the global herpes simplex virus (HSV) treatment market include an increasing prevalence of herpes infections, rising awareness about available treatment options, and the growing demand for effective therapies. Increasing adoption of antiviral drugs and the development of novel treatment approaches are further contributing to market growth. Herpes simplex, a widespread strain of the herpes virus, affects a substantial portion of the global population, with approximately 3.7 billion individuals estimated to be impacted. This highly contagious infection can be transmitted through various bodily fluids such as saliva, vaginal secretions, or semen, often without the carrier's knowledge. Also, there has been a noticeable rise in human herpesvirus lytic reactivation among COVID-19 patients, including those who have received vaccinations, during the forecast period. However, prevalent side effects of most used herpes medications are anticipated to restrain the global herpes simplex virus (HSV) treatment market growth.

Global Herpes Simplex Virus (HSV) Treatment Market - Overview:

The global herpes simplex virus (HSV) treatment market refers to the collective market for pharmaceutical products, therapies, and interventions used in the management and treatment of herpes infections caused by the herpes simplex virus. This market encompasses various treatment options, including antiviral medications, topical creams, vaccines, and other therapeutic approaches aimed at reducing the severity of outbreaks, alleviating symptoms, and suppressing viral replication. The market is driven by the increasing prevalence of herpes infections globally, the growing demand for effective treatment options, and ongoing research and development efforts to improve therapeutic outcomes.

Impact of COVID-19 on Global Herpes Simplex Virus (HSV) Treatment Market:

COVID-19 pandemic had a dual impact on the global herpes simplex virus (HSV) treatment market. On the one hand, the increased focus on healthcare and hygiene practices raised awareness about the importance of managing infectious diseases like HSV. It increased the demand for HSV treatments. On the other hand, the diversion of healthcare resources and disruption of supply chains as the pandemic posed challenges for accessing and delivering HSV treatments. Also, the prioritization of COVID-19-related research and development temporarily slowed down advancements in HSV treatment options. The overall impact of COVID-19 on the global herpes simplex virus (HSV) treatment market remains complex and may vary across regions.

Global Herpes Simplex Virus (HSV) Treatment Market - By Drug Type:

Based on drug type, the global herpes simplex virus (HSV) treatment market is divided into Acyclovir, Valacyclovir, and Famciclovir segments. Valacyclovir segment held the highest share in the global herpes simplex virus treatment market during 2022. This can be attributed to its cost-effectiveness, wide availability, and remarkable efficacy in inhibiting the replication of the herpes virus within the body, thus effectively managing the symptoms associated with herpes outbreaks. Valacyclovir is particularly favored for its superior absorption rate compared to acyclovir, making it a preferred choice for treating cold sores, as oral acyclovir is susceptible to rapid breakdown by the liver. Also, a study published in the American Journal of Ophthalmology has demonstrated the comparable effectiveness of a 500 mg valacyclovir dose in preventing the recurrence of HSV eye disease to that of an 800 mg acyclovir dose. Meanwhile, the acyclovir segment is expected to witness fastest growth during the forecast period. This can be attributed to the widespread acceptance of acyclovir as the industry benchmark for the treatment of herpes infections. Also, the market's growth is fueled by the introduction of over-the-counter drugs for infection treatment.

Competitive Landscape:

Major players operating in the global herpes simplex virus treatment market include: Abbott Laboratories, Pfizer Inc., Amneal Pharmaceuticals Inc., GlaxoSmithKline PLC, Teva Pharmaceuticals Industries Ltd, Glenmark Pharmaceuticals Limited, Fresenius SE & Co. KGaA, Novartis AG, Viatris Inc., and Emcure Pharmaceuticals Limited. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of Global Herpes Simplex Virus (HSV) Treatment Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Global Herpes Simplex Virus (HSV) Treatment Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

2. Executive Summary

3. Global Herpes Simplex Virus (HSV) Treatment Market Insights

  • 3.1. Industry Value Chain Analysis
  • 3.2. DROC Analysis
    • 3.2.1. Growth Drivers
      • 3.2.1.1. Increasing prevalence of herpes simplex virus infections
      • 3.2.1.2. Rising development of HSV testing and medications
    • 3.2.2. Restraints
      • 3.2.2.1. Prevalent side effects of most used herpes medications
    • 3.2.3. Opportunities
      • 3.2.3.1. Increase in R&D activities
      • 3.2.3.2. High growth potential in developing economies
    • 3.2.4. Challenges
      • 3.2.4.1. Stigma associated with herpes simplex virus
  • 3.3. Technological Advancements/Recent Developments
  • 3.4. Regulatory Framework
  • 3.5. Porter's Five Forces Analysis
    • 3.5.1. Bargaining Power of Suppliers
    • 3.5.2. Bargaining Power of Buyers
    • 3.5.3. Threat of New Entrants
    • 3.5.4. Threat of Substitutes
    • 3.5.5. Intensity of Rivalry
  • 3.6. Price Point Analysis: Global Automotive Memory, 2019-2022

4. Global Herpes Simplex Virus (HSV) Treatment Market Overview

  • 4.1. Market Size & Forecast by Value, 2019-2029
    • 4.1.1. By Value (USD Billion)
  • 4.2. Market Share & Forecast
    • 4.2.1. By Type
      • 4.2.1.1. Herpes simplex virus-1 infection
      • 4.2.1.2. Herpes simplex virus-2 infection
    • 4.2.2. By Drug Type
      • 4.2.2.1. Acyclovir
      • 4.2.2.2. Valacyclovir
      • 4.2.2.3. Famciclovir
    • 4.2.3. By Distribution Channel
      • 4.2.3.1. Hospital pharmacies
      • 4.2.3.2. Drug store and retail pharmacies
      • 4.2.3.3. Online providers
    • 4.2.4. By Region
      • 4.2.4.1. North America
      • 4.2.4.2. Europe
      • 4.2.4.3. Asia Pacific (APAC)
      • 4.2.4.4. Latin America (LATAM)
      • 4.2.4.5. Middle East and Africa (MEA)

5. North America Herpes Simplex Virus (HSV) Treatment Market

  • 5.1. Market Size & Forecast by Value, 2019-2029
    • 5.1.1. By Value (USD Billion)
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type
    • 5.2.2. By Drug Type
    • 5.2.3. By Distribution Channel
    • 5.2.4. By Country
      • 5.2.4.1. United States
      • 5.2.4.1.1. By Type
      • 5.2.4.1.2. By Drug Type
      • 5.2.4.1.3. By Distribution Channel
      • 5.2.4.2. Canada
      • 5.2.4.2.1. By Type
      • 5.2.4.2.2. By Drug Type
      • 5.2.4.2.3. By Distribution Channel

6. Europe Herpes Simplex Virus (HSV) Treatment Market

  • 6.1. Market Size & Forecast by Value, 2019-2029
    • 6.1.1. By Value (USD Billion)
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Drug Type
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
      • 6.2.4.1. Germany
      • 6.2.4.1.1. By Type
      • 6.2.4.1.2. By Drug Type
      • 6.2.4.1.3. By Distribution Channel
      • 6.2.4.2. United Kingdom
      • 6.2.4.2.1. By Type
      • 6.2.4.2.2. By Drug Type
      • 6.2.4.2.3. By Distribution Channel
      • 6.2.4.3. Italy
      • 6.2.4.3.1. By Type
      • 6.2.4.3.2. By Drug Type
      • 6.2.4.3.3. By Distribution Channel
      • 6.2.4.4. France
      • 6.2.4.4.1. By Type
      • 6.2.4.4.2. By Drug Type
      • 6.2.4.4.3. By Distribution Channel
      • 6.2.4.5. Spain
      • 6.2.4.5.1. By Type
      • 6.2.4.5.2. By Drug Type
      • 6.2.4.5.3. By Distribution Channel
      • 6.2.4.6. The Netherlands
      • 6.2.4.6.1. By Type
      • 6.2.4.6.2. By Drug Type
      • 6.2.4.6.3. By Distribution Channel
      • 6.2.4.7. Rest of Europe
      • 6.2.4.7.1. By Type
      • 6.2.4.7.2. By Drug Type
      • 6.2.4.7.3. By Distribution Channel

7. Asia-Pacific Herpes Simplex Virus (HSV) Treatment Market

  • 7.1. Market Size & Forecast by Value, 2019-2029
    • 7.1.1. By Value (USD Billion)
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Drug Type
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
      • 7.2.4.1. China
      • 7.2.4.1.1. By Type
      • 7.2.4.1.2. By Drug Type
      • 7.2.4.1.3. By Distribution Channel
      • 7.2.4.2. India
      • 7.2.4.2.1. By Type
      • 7.2.4.2.2. By Drug Type
      • 7.2.4.2.3. By Distribution Channel
      • 7.2.4.3. Japan
      • 7.2.4.3.1. By Type
      • 7.2.4.3.2. By Drug Type
      • 7.2.4.3.3. By Distribution Channel
      • 7.2.4.4. South Korea
      • 7.2.4.4.1. By Type
      • 7.2.4.4.2. By Drug Type
      • 7.2.4.4.3. By Distribution Channel
      • 7.2.4.5. Australia & New Zealand
      • 7.2.4.5.1. By Type
      • 7.2.4.5.2. By Drug Type
      • 7.2.4.5.3. By Distribution Channel
      • 7.2.4.6. Indonesia
      • 7.2.4.6.1. By Type
      • 7.2.4.6.2. By Drug Type
      • 7.2.4.6.3. By Distribution Channel
      • 7.2.4.7. Malaysia
      • 7.2.4.7.1. By Type
      • 7.2.4.7.2. By Drug Type
      • 7.2.4.7.3. By Distribution Channel
      • 7.2.4.8. Singapore
      • 7.2.4.8.1. By Type
      • 7.2.4.8.2. By Drug Type
      • 7.2.4.8.3. By Distribution Channel
      • 7.2.4.9. Philippines
      • 7.2.4.9.1. By Type
      • 7.2.4.9.2. By Drug Type
      • 7.2.4.9.3. By Distribution Channel
      • 7.2.4.10. Vietnam
      • 7.2.4.10.1. By Type
      • 7.2.4.10.2. By Drug Type
      • 7.2.4.10.3. By Distribution Channel
      • 7.2.4.11. Rest of APAC
      • 7.2.4.11.1. By Type
      • 7.2.4.11.2. By Drug Type
      • 7.2.4.11.3. By Distribution Channel

8. Latin America Herpes Simplex Virus (HSV) Treatment Market

  • 8.1. Market Size & Forecast by Value, 2019-2029
    • 8.1.1. By Value (USD Billion)
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Drug Type
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
      • 8.2.4.1. Brazil
      • 8.2.4.1.1. By Type
      • 8.2.4.1.2. By Drug Type
      • 8.2.4.1.3. By Distribution Channel
      • 8.2.4.2. Mexico
      • 8.2.4.2.1. By Type
      • 8.2.4.2.2. By Drug Type
      • 8.2.4.2.3. By Distribution Channel
      • 8.2.4.3. Argentina
      • 8.2.4.3.1. By Type
      • 8.2.4.3.2. By Drug Type
      • 8.2.4.3.3. By Distribution Channel
      • 8.2.4.4. Peru
      • 8.2.4.4.1. By Type
      • 8.2.4.4.2. By Drug Type
      • 8.2.4.4.3. By Distribution Channel
      • 8.2.4.5. Colombia
      • 8.2.4.5.1. By Type
      • 8.2.4.5.2. By Drug Type
      • 8.2.4.5.3. By Distribution Channel
      • 8.2.4.6. Rest of LATAM
      • 8.2.4.6.1. By Type
      • 8.2.4.6.2. By Drug Type
      • 8.2.4.6.3. By Distribution Channel

9. Middle East & Africa Herpes Simplex Virus (HSV) Treatment Market

  • 9.1. Market Size & Forecast by Value, 2019-2029
    • 9.1.1. By Value (USD Billion)
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Drug Type
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
      • 9.2.4.1. Saudi Arabia
      • 9.2.4.1.1. By Type
      • 9.2.4.1.2. By Drug Type
      • 9.2.4.1.3. By Distribution Channel
      • 9.2.4.2. UAE
      • 9.2.4.2.1. By Type
      • 9.2.4.2.2. By Drug Type
      • 9.2.4.2.3. By Distribution Channel
      • 9.2.4.3. Qatar
      • 9.2.4.3.1. By Type
      • 9.2.4.3.2. By Drug Type
      • 9.2.4.3.3. By Distribution Channel
      • 9.2.4.4. Kuwait
      • 9.2.4.4.1. By Type
      • 9.2.4.4.2. By Drug Type
      • 9.2.4.4.3. By Distribution Channel
      • 9.2.4.5. South Africa
      • 9.2.4.5.1. By Type
      • 9.2.4.5.2. By Drug Type
      • 9.2.4.5.3. By Distribution Channel
      • 9.2.4.6. Nigeria
      • 9.2.4.6.1. By Type
      • 9.2.4.6.2. By Drug Type
      • 9.2.4.6.3. By Distribution Channel
      • 9.2.4.7. Algeria
      • 9.2.4.7.1. By Type
      • 9.2.4.7.2. By Drug Type
      • 9.2.4.7.3. By Distribution Channel
      • 9.2.4.8. Rest of MEA
      • 9.2.4.8.1. By Type
      • 9.2.4.8.2. By Drug Type
      • 9.2.4.8.3. By Distribution Channel

10. Competitive Landscape

  • 10.1. List of Key Players and Their Offerings
  • 10.2. Global Herpes Simplex Virus (HSV) Treatment Products Company Market Share Analysis, 2022
  • 10.3. Competitive Benchmarking, By Operating Parameters
  • 10.4. Key Strategic Development (Mergers, Acquisitions, Partnerships, etc.)

11. Impact of Covid-19 on Global Herpes Simplex Virus (HSV) Treatment Market

12. Company Profile (Company Overview, Financial Matrix, Competitive landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook and SWOT Analysis)

  • 12.1. Abbott Laboratories
  • 12.2. Pfizer, Inc.
  • 12.3. Amneal Pharmaceuticals, Inc.
  • 12.4. GlaxoSmithKline PLC
  • 12.5. Teva Pharmaceuticals Industries Ltd.
  • 12.6. Glenmark Pharmaceuticals Limited
  • 12.7. Fresenius SE & Co. KGaA
  • 12.8. Novartis AG
  • 12.9. Viatris, Inc.
  • 12.10. Emcure Pharmaceuticals Limited
  • 12.11. Other Prominent Players

13. Key Strategic Recommendations

14. Research Methodology

  • 14.1. Qualitative Research
    • 14.1.1. Primary & Secondary Research
  • 14.2. Quantitative Research
  • 14.3. Market Breakdown & Data Triangulation
    • 14.3.1. Secondary Research
    • 14.3.2. Primary Research
  • 14.4. Breakdown of Primary Research Respondents, By Region
  • 14.5. Assumption & Limitation